Back to Trials
NCT05224089PHASE4Recruiting

Bilateral TAP and RS Blocks Using Liposomal Bupivacaine/Bupivacaine vs. Regular Bupivacaine in Laparoscopic Colectomy

Hartford Hospital

Start Date

4/27/2022

Completion Date

2/1/2026

Summary

This study will be a single center, prospective triple blinded randomized controlled study, comparing the use of liposomal bupivacaine (Exparel) to regular bupivacaine with adjuncts in bilateral mid-abdominal transverse abdominis plane (TAP) blocks for patients undergoing laparoscopic colectomy procedures.

Eligibility Criteria

Age Range: 18 years to No maximum

Inclusion Criteria: * Patients scheduled for elective laparoscopic colectomy surgery to be performed by one of the 4 colorectal surgeons in the study. * English speaking patients * Patients with American Society of Anesthesiology (ASA) physical status score I- IV Exclusion Criteria: 1. Emergency laparoscopic colectomy surgery 2. Patients with distant metastatic cancers (e.g. bone, lung, brain). 3. Scheduled for multi organs resection surgery in addition to colectomy. 4. Patients with contraindications to TAP or RS blocks including but not limited to anatomical abnormality, previous surgical intervention that limits or prevents receiving bilateral TAP blocks (e.g. surgical mesh at the site of TAP or RS block), or infection at the injection site. 5. Current colostomies. 6. History of allergy to local anesthetics. 7. Coagulopathy or coagulation disorder. Also patients who are receiving antithrombotic medications as a contraindication to receiving single shot peripheral nerve blockade as per the most recent American Society of Regional Anesthesiology (ASRA) guidelines.16 8. Weight \< 40 kg, as 40 mL of Bupivacaine 0.25%, or combination of 20 mL of bupivacaine 0.25% with 20 mL of liposomal bupivacaine is greater than the maximal dose allowed, given concern for local anesthetic toxicity. 9. Patients who take long acting opioid medication, or on continuous opioid \> 50 MME per day for at least 30 days within 90 days prior to surgery. Also patients who have chronic pain syndrome with a recent preoperative consultation to the chronic pain service. 10. Patients with current substance abuse, or history of substance abuse within 3 months, this includes any illicit drugs or excessive alcohol consumption as defined 4 or more drinks per day or 8 or more drinks per week for women and 5 or more drinks per day or 15 or more drinks per week for men.15 11. Pregnant, nursing, or planning to become pregnant during the study or within 1 month postoperatively 12. Refusal or lack of providing the study consent

Interventions

DRUG

Liposomal Bupivicaine/Bupivacaine Admixture

DRUG

Bupivacaine HCL

Interested in This Trial?

Contact the trial locations directly using the information below to learn more about enrollment.

Expressing interest lets you review the study and consent before we connect you with the research site.

Conditions

Bowel Disease

Locations

Hartford Hospital

Hartford, Connecticut 06102

United States